SUPPORTIVE CARE IN HEMATOONCOLOGY

[1]  S. Khan,et al.  Current understanding of tumor lysis syndrome , 2019, Hematological oncology.

[2]  M. Kersten,et al.  Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) , 2019, Haematologica.

[3]  R. Storb,et al.  Total Body Irradiation–Based versus Chemotherapy-Based Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplant , 2019 .

[4]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[5]  F. Valour,et al.  Vaccination post-allogeneic hematopoietic stem cell transplantation: what is feasible? , 2018, Expert review of vaccines.

[6]  M. Aapro,et al.  A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Bruzzi,et al.  Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. , 2018, The Journal of infection.

[8]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[9]  W. Mccune,et al.  Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy , 2017, Current opinion in rheumatology.

[10]  Wei Liu,et al.  Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis , 2017, BMC Infectious Diseases.

[11]  A. Busca,et al.  Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation , 2016, Expert review of hematology.

[12]  S. Corey,et al.  G-CSF and GM-CSF in Neutropenia , 2015, The Journal of Immunology.

[13]  P. Ljungman,et al.  Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection? , 2015, Bone Marrow Transplantation.

[14]  J. Boulanger,et al.  Management of the extravasation of anti-neoplastic agents , 2015, Supportive Care in Cancer.

[15]  M. Peeters,et al.  Use of antiemetics in the prevention of chemotherapy-induced nausea and vomiting: review and focus on the Belgian situation. , 2014, Acta gastro-enterologica Belgica.

[16]  M. Reich.  [Depression in oncology]. , 2010, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[17]  S. Langer.  Extravasation of Chemotherapy , 2010, Current oncology reports.

[18]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[19]  A. del Palacio,et al.  [Early diagnosis of invasive aspergillosis in neutropenic patients with bi-weekly serial screening of circulating galactomannan by Platelia Aspergillus]. , 2003, Revista iberoamericana de micologia.

[20]  H. Deeg.  Acute and delayed toxicities of total body irradiation. Seattle Marrow Transplant Team. , 1983, International journal of radiation oncology, biology, physics.

[21]  T. Walsh,et al.  Prevention of infection among patients with cancer. , 1983, European journal of cancer & clinical oncology.